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Summary
Objective: This study aims to assess the current antipsych-
otic prescribing trends for the treatment of schizophrenia
and to compare them with available guidelines and research
evidence.
Design: An observational retrospective quantitative
analysis.
Setting: Data were collected from the prescribing cost ana-
lysis for the period between 2007 and 2014, including all
drugs from the British National Formulary 4.2.1 and 4.2.2.
Prescriptions were included from primary and secondary
healthcare settings in England and Wales.
Participants: None.
Main outcome measures: Defined daily doses of antipsych-
otics were used to compare popularity of individual drugs
and classes of antipsychotics.
Results: There is a consistent increase in the proportion
of atypical antipsychotics prescribed, compared to typical
antipsychotics, between 2007 and 2014, with atypicals
accounting for 79.9% of total antipsychotics prescribed in
2014.
Conclusion: The consistent popularity of atypical anti-
psychotics is not concordant with the current National
Institute for Health and Care Excellence guidelines for
the treatment of schizophrenia or the most recent research
evidence.
Keywords
Psychotic disorders, guidelines, medicines regulation, chan-
ging physician behaviour
Introduction
Schizophrenia is a severe, chronic mental disorder
with a worldwide global risk of 0.72%.1 Clinical pres-
entation and response to medication are extremely
varied, which can mean it is very difficult to decide
what treatment to offer.
Treatment of schizophrenia focuses on the use
of antipsychotics. Generally, these are categorised
into two groups: typical or first-generation antipsych-
otics and atypical or second-generation antipsych-
otics. Both act on dopamine receptors, in particular
D2, which accounts for their antipsychotic effects.2,3
Typical antipsychotics are less selective in their site
of action than atypical antipsychotics. As a result,
some may worsen negative symptoms (due to their
action in the mesocortical pathway) and can produce
unwanted extrapyramidal side effects, such as
acute dystonias, tardive dyskinesia and parkinsonian
symptoms (due to their action in the nigrostriatal
pathway).4
Typical and atypical antipsychotics differ in their
pharmaceutical properties, the effect they have on the
symptoms and their side-effect profile. Although atyp-
ical antipsychotics also block D2 receptors, it is
thought that they dissociate more quickly than typ-
icals. Some have additional action at serotonin recep-
tors – there is evidence that this leads to a reduction in
the number and severity of extrapyramidal side effects
experienced by patients.4 They do, however, cause
other adverse reactions, which can be just as severe
and debilitating, including metabolic syndrome.5
Clozapine is known to be associated with agranulo-
cytosis; for this reason, clozapine is only considered
as a third-line treatment for patients with refractory
schizophrenia.Any patientwho is prescribed clozapine
must be closely monitored with regular blood counts.6
Certain drugs from either class of antipsychotics
can be associated with sexual dysfunction and hyper-
prolactinaemia; however, the effect depends on the
individual drug and the dose used.7,8
The first National Institute for Health and Care
Excellence guidelines published (2002) focused on the
treatment of schizophrenia andadvised that, in the case
of first presentation schizophrenia, first-line treatment
should be an atypical antipsychotic (specifically ami-
sulpride, olanzapine, quetiapine, risperidone and zote-
pine). They state that when the treatment options
cannot be discussed, such as in the case of an acute
schizophrenic episode, atypicals should be used due
to their lower risk of extrapyramidal side effects.9
However, after publication of these guidelines,
the research used in their production was re-assessed
and found to be flawed. This initiated further inves-
tigation into the efficacy and side-effect profile of
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typical versus atypical antipsychotics, which yielded
findings contrary to the guidance published by the
National Institute for Health and Care Excellence.
This research includes the Clinical Antipsychotic
Trials of Intervention Effectiveness, a quantitative
study by Lieberman and Stroup, which investigated
the effectiveness of atypical antipsychotics in compari-
son to typical antipsychotics, used in the treatment of
schizophrenic patients.10 Jones et al. conducted a ran-
domised control trial (known as CUtLASS 1) with the
objective of finding out whether the extra cost of atyp-
ical antipsychotics is accounted for by improvements
in quality of life or reduced costs in other health and
social care services.11 While this trial rejected their
hypothesis that atypicals are superior to typicals, the
question remains whether some individual atypical
antipsychotics are more advantageous. Geddes
et al.12 produced a meta-analysis investigating the
effect of certain antipsychotics on symptom control
and their overall acceptability to patients. An import-
ant result of this study is the affirmation that using
typical antipsychotic drugs at high doses does not
improve their efficacy but increases side effects experi-
enced.12 The use of typical antipsychotics at high
doses may account for the initial misleading evidence.
The result was that, in 2009, the National Institute
for Health and Care Excellence guidelines were chan-
ged so that the advice was simply, ‘for people with
newly diagnosed schizophrenia, offer oral antipsych-
otic medication. Provide information and discuss the
benefits and side effect profile of each drug with the
service user’. The same advice is given for acute epi-
sodes of schizophrenia, and there is no clearly stated
preference for atypical over typical antipsychotics.13
Although there has been some research investigat-
ing antipsychotic prescribing trends following the
2002 guidelines, there are few studies which look at
trends following the changes to the guidelines in 2009.
Verdoux et al.14 looked at published studies between
2000 and 2008 which analysed antipsychotic prescrib-
ing in the general population. They concluded that
overall antipsychotic prescribing has increased. This
increase was most commonly related to an increase in
atypical antipsychotics. Some of the included studies
reported up to an 89% increase in atypical antipsych-
otic prescribing.
This paper aims to assess more recent prescribing
trends in order to find out whether clinical practice has
changed in response to evolving research and guidance.
Methods
This analysis was carried out using data collected
from the prescribing cost analysis for antipsychotic
drugs included in the British National Formulary
4.2.1 and 4.2.2.15 Included were all prescriptions
between 2006 and 2014 in England and Wales.
These data were presented as the number of defined
daily doses, rather than items prescribed.
The World Health Organisation defines a daily
dose as, ‘The defined daily dose is the assumed aver-
age maintenance dose per day for a drug used for its
main indication in adults’.16 The defined daily dose
does not always match the prescribed or recom-
mended daily dose. The defined daily dose for indi-
vidual patients will be different, as it should be based
on individual patients and pharmacokinetics.
These data were presented using defined daily
doses as it can give an estimate of drug consumption.
In this study, an estimate can be used and not exact
quantities as it is comparing trends over a period of
time involving a large quantity of drugs.
There are limitations to using this format of data
because there are alternative uses for some of the
antipsychotics including the treatment of agitation
in dementia and mood disorders. To mitigate for
this confounding factor, British National Formulary
4.2.1 and 4.2.2 were consulted and 26 antipsychotics
preparations were eliminated which are unlikely to be
used in schizophrenia, either due to the dose pre-
scribed or the preparation used. To ascertain this,
the British National Formulary, medicines.com and
clinical experience from practitioners was used. The
preparations removed were all prescribed at a low
frequency, suggesting that they are not used com-
monly in mainstream practice.
Data from March 2007 to December 2014 were
quantitatively analysed, comparing the frequency and
distribution of antipsychotic prescribing over time. A
comparison was made using Excel software between
the prescribing percentages of typical versus atypical
antipsychotics bydividing them into twobroad groups.
In addition, individual drugs were analysed in greater
depth. The typical antipsychotics selected were perpe-
henazine, chlorpromazine, haloperidol, zuclo-
penthixol, flupenthixol and sulpiride. The atypicals
selected were olanzapine, quetiapine, risperidone, ami-
sulpride, zotepine and clozapine. This selection was
based on antipsychotics that are most commonly pre-
scribed and those included in the most recent research
including the CATIE and CUtLASS trials. They
included liquid form, depot preparation and tablets.
Results
There has been a consistent yearly change in the pro-
portion of typical versus atypical antipsychotics, a
year on year increase in atypicals, culminating in an
end of study period high of 79.9% of total antipsych-
otics prescribed (Figure 1).
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Despite an early increase in some of the individual
typical antipsychotics, there is a general downwards
trend. The largest decrease can be seen with chloro-
promazine; however, there is a general increase in
zuclopenthixol and flupenthixol. At the end of the
study period, zuclopenthixol is the most popular typ-
ical, with 5,244,935 defined daily doses being pre-
scribed in 2014 (Figure 2).
Figure 3 shows the changes in atypical antipsych-
otic prescribing. These charts correspond with the
trend seen in Figure 1 in that all of the atypical anti-
psychotics increase during the study period.
The largest increase is seen with quetiapine; the
defined daily doses of quetiapine increased by
17,900,716 between 2007 and 2014. With regard to
clozapine, there is a small increase in the defined
daily doses prescribed over the study period of 3454.
When comparing the most commonly prescribed
typical and atypical antipsychotics in 2007 and 2014
(Table 1), it is clear that the drugs most popular at the
start of the study period have become more fre-
quently prescribed as compared to other antipsych-
otics, which are represented by the blank portion of
the graph. Despite the strong evidence for the high
efficacy of clozapine, this drug only makes up 0.1% of
the atypical antipsychotics both in 2007 and 2014.
The greatest increases in the proportion of typical
and atypical prescriptions are seen in zuclopentixol
and quetiapine, respectively; however there are no
dramatic reductions in any of the individual anti-
psychotics which suggest they these increases are
replacing other, less frequently prescribed antipsych-
otics (Figure 4).
Discussion
These results highlight important aspects relating to
guideline implementation and knowledge translation.
The increasing trend in atypical antipsychotics can be
seen in Figure 1 and continues following the intro-
duction of the 2009 the National Institute for Health
and Care Excellence guidelines, despite the change in
recommendations.
One limitation of this study is the inability to
definitively say which medication was used to treat
schizophrenia and what was used in other situations.
Figure 1. Radar graph showing the general trend in atypical vs. typical antipsychotic prescribing between 2007 and 2014.
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This means that the trends identified may not be due
to changes in antipsychotic prescribing in schizophre-
nia. While the authors have done their best to ensure
the removal of doses that are unlikely to be prescribed
for schizophrenia, dose titration or treatment aug-
mentation must be considered. For example,
augmentation can be used to reduce side effects as
in the case of aripiprazole where mixed therapy
helps to control the dysregulation of prolactin levels.
While a strength of this study is the large amount
of data collected, there is no accounting for variation
between data centres. In a previous study, a large
Figure 3. Line graph showing the changes in atypical antipsychotic prescribing between 2007 and 2014, with the changes in
clozapine and zotepine highlighted.
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Figure 2. Line graph showing the changes in typical antipsychotic prescribing between 2007 and 2014.
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variation was seen between medical centres.
The study found that medical centres with fewer
patients with severe mental illness had higher rates
of polypharmacy. This suggests that clinician experi-
ence has a link with adherence to clinical guidelines,
particularly in the cases of severe mental illness.17
An important part of the guidelines is the gold
standard use of clozapine in treatment-resistant
schizophrenia. Between 2008 and 2014, there was
only a small increase in the frequency of clozapine
prescriptions (Figure 3). This smaller than expected
increase could be due to a delay in clozapine use.
This delay has been identified in other research,
where clozapine use is preceded by antipsychotic
polypharmacy.17 The reduction in clozapine could
be an effect of increased patient awareness and clin-
ician apprehension of potentially fatal agranulocyto-
sis and the need for increased rigorous monitoring.
Table 1. Defined daily dose of selected antipsychotics rounded to the nearest decimal place.
Antipsychotics 2007 2008 2009 2010 2011 2012 2013 2014
Zuclopenthixol 2,896,307 4,814,550 5,671,732 4,987,741 5,036,666 5,088,718 5,216,819 5,244,936
Haloperidol 4,922,344 6,549,801 6,225,268 5,977,327 5,521,783 5,327,450 5,249,117 5,157,594
Flupenthixol 3,647,639 3,908,568 3,962,958 4,036,929 4,156,676 4,296,018 4,334,184 4,328,550
Chlorpromazine 3,973,965 3,872,806 3,617,034 3,373,057 3,194,222 3,037,586 2,861,237 2,675,197
Sulpiride 2,331,210 3,078,441 2,956,614 2,815,235 2,712,167 2,647,792 2,606,160 2,555,799
Perphenazine 82,624 129,319 139,835 127,286 120,206 76,866 10,976 5000
Olanzapine 25,258,798 34,018,851 32,932,892 36,100,730 37,268,466 38,447,751 38,853,086 39,993,225
Quetiapine 5,816,796 8,865,783 10,559,849 12,829,882 15,717,863 18,900,611 21,582,519 23,717,512
Risperidone 10,479,452 14,238,391 14,617,122 14,681,499 15,081,681 15,607,863 16,020,777 16,360,724
Amisulpride 4,412,009 6,048,136 6,329,566 6,380,441 6,430,853 6,468,062 6,615,597 6,651,805
Zotepine 493,960 515,083 507,300 500,946 508,746 503,550 525,658 548,105
Clozapine 68,126 96,117 102,037 100,516 98,953 87,816 80,551 71,581
Figure 4. Donut chart showing the proportion of prescription of six typical and six atypical antipsychotics; 2007 is on the left and
2014 is on the right.
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Additionally, the last few years have seen the wide-
spread introduction of new atypicals such as depot
paliperidone and lurasidone, which provides more
options to prescribers who may favour these medi-
cines to clozapine.
The dramatic rise in quetiapine prescriptions may
be due to its increased use for the treatment of mood
disorders, rather than schizophrenia. Its increased use
is unlikely to be due to treatment of schizophrenia
due to its reduced clinical efficacy compared to
other antipsychotic agents.18
Olanzapine is associated with the greatest weight
gain and most severe metabolic side effects. Due to
this effect, Schizophrenia Patient Outcome Research
Team suggests that olanzapine should not be used as
first-line treatment unless it gives significant thera-
peutic benefits.19 Despite such guidance, olanzapine
is the most dominant antipsychotic and it continues
to show a consistent increase. This may be due to the
recent introduction of depot preparations or the
introduction of local policies, which have improved
metabolic monitoring. This improvement may have
led to an increased confidence in the ability to safely
prescribe olanzapine and manage the associated side
effects. Despite improvements, the increase seen with
olanzapine remains a worrying trend as during the
last years there has been a rise in the mortality
risk associated with schizophrenia. While the increase
in mortality can partly be accounted for by suicide
metabolic syndrome is associated with a two-fold
increase in mortality.1 Future research may be
aimed at investigating whether the increased use of
olanzapine is affecting the mortality risk associated
with schizophrenia.
The above increase in the prescribing of atypical
antipsychotics appears to be matched by a decrease in
typical antipsychotic prescribing. The biggest reduc-
tion can be seen in the prescribing of haloperidol,
while zuclopenthixol appears to go against the trend
and increases. Haloperidol is associated with high
rates of extrapyramidal side effects.19 The reduction
in haloperidol use could be accounted for by
increased patient awareness of these side effects and
their refusal to accept treatment with these risks.
Due to the increasing trend towards using atypical
antipsychotics there will be a reduced level of experi-
ence with typical antipsychotics. Reduced clinical
experience with typical antipsychotics will likely
mean that clinicians are not as comfortable using
these drugs, advocating their use or treating the side
effects. This will contribute towards a continued
decreasing use of typical antipsychotics. The increas-
ing use of zuclopenthixol is likely due to the fact that
it has replaced some discontinued drugs during the
study period. The significant increase in the use of
this drug in particular may be due to the inclusion
of depot injections.
A meta-analysis conducted by Leucht et al.18 com-
pared the efficacy and side-effect profile of typical and
atypical antipsychotics with a placebo. Large differ-
ences were found in terms of side effects; in concord-
ance with previous research, olanzapine produced
greatest weight gain and haloperidol the greatest
extrapyramidal side effects. Smaller differences were
seen when comparing efficacy, with clozapine being
the most effective drug. The authors suggest that if
antipsychotics were organised into a hierarchy within
different domains, rather than categorised into two
groups, clinicians would be able to provide more indi-
vidualised treatment for each patient.16
Many healthcare professionals who work within
the field of mental health use the Maudsley guide-
lines.13 Within this speciality, there may be a heavier
reliance on these guidelines compared to National
Institute for Health and Care Excellence guidelines.
Previous Maudsley guidelines specifically
advocated the use of an atypical antipsychotic in
first-episode schizophrenia. However, more recent
guidelines agree with the National Institute for
Health and Care Excellence guidance and they high-
light that different people respond differently to dif-
ferent treatments, and that individual drugs have
certain benefits. The previous conflicting information
between guidelines may have led to a degree of uncer-
tainty for practitioners.
However, while there may have been previously
conflicting guidelines, it is important that practi-
tioners stay up-to-date and rely on other forms of
evidence including randomised control trial data
and reviews. Certain patients may benefit more
from typical antipsychotics; therefore, it is important
that their use is not ruled out by clinicians who are
not aware of the current evidence. The prescribing
data seen in this study suggest that this evidence is
not being translated into current practice.
It has been recognised that there are four types of
evidence that contribute to care. These are: research,
clinical experience, patient experience and local infor-
mation.20 One study found that GP practices that
ranked highly in terms of prescribing quality were
those in which doctors made both macro and micro
decisions.21
Macro decisions are governed by policy and allow
decisions to be research based and consistent. Micro
decisions, however, are based on individual patient
characteristics. It is suggested that micro decisions,
and therefore individual patient prescribing, must be
guided by macro decisions to ensure evidence-based
prescribing.21 Local practices and policies are there-
fore important in guiding prescribing decisions
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including input from specialist pharmacists or prac-
tice formularies.
The results of this study confirm the hypothesis
that there has been no change in the frequency of
prescriptions of typical or atypical antipsychotic
drugs following changes to National Institute for
Health and Care Excellence guidelines.
Furthermore, it offers insight into why clinical prac-
tice does not seem to reflect the available research
evidence in terms of treating schizophrenia.
To assess the importance of clinical experience in
prescribing behaviour, a follow-up thematic analysis
study could establish additional factors influencing
clinicians’ prescribing.
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